Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (81-90 of 155) with videos related to

Pageof 16
Sort By:
Clinical Diabetes : a Publication of the American Diabetes Association|February 2, 2019
A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 DiabetesKurt Midyett, Jeffrey R Unger, Eugene E Wright, et al.
Diabetes, Obesity & Metabolism|March 2, 2018
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trialsRobert R Henry, Dirk Müller-Wieland, Pam R Taub, et al.
Diabetes Care|February 16, 2013
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDavid Polidori, Sue Sha, Sunder Mudaliar, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 30, 2010
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetesKwang-Hoon Chun, Kang-Duk Choi, Dae-Ho Lee, et al.
Metabolism: Clinical and Experimental|May 22, 2003
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposalOdile Mathieu-Costello, Alice Kong, Theodore P Ciaraldi, et al.
Plos One|September 26, 2018
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetesRobert R Henry, Juan P Frias, Brandon Walsh, et al.
Journal of the American Dietetic Association|December 4, 2003
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetesV Lee Grotz, Robert R Henry, Janet B McGill, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 8, 2006
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissueTheodore P Ciaraldi, Deborah K Oh, Louis Christiansen, et al.
The Annals of Pharmacotherapy|November 8, 2015
Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex PatientsCandis M Morello, Melissa L D Christopher, Linda Ortega, et al.
Diabetes|January 29, 2002
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjectsYoung-Bum Kim, Theodore P Ciaraldi, Alice Kong, et al.
Pageof 16

Showing results (81-90 of 155) with videos related to

Sort By:
Pageof 16
Clinical Diabetes : a Publication of the American Diabetes Association|February 2, 2019
A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 DiabetesKurt Midyett, Jeffrey R Unger, Eugene E Wright, et al.
Diabetes, Obesity & Metabolism|March 2, 2018
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trialsRobert R Henry, Dirk Müller-Wieland, Pam R Taub, et al.
Diabetes Care|February 16, 2013
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDavid Polidori, Sue Sha, Sunder Mudaliar, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 30, 2010
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetesKwang-Hoon Chun, Kang-Duk Choi, Dae-Ho Lee, et al.
Metabolism: Clinical and Experimental|May 22, 2003
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposalOdile Mathieu-Costello, Alice Kong, Theodore P Ciaraldi, et al.
Plos One|September 26, 2018
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetesRobert R Henry, Juan P Frias, Brandon Walsh, et al.
Journal of the American Dietetic Association|December 4, 2003
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetesV Lee Grotz, Robert R Henry, Janet B McGill, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 8, 2006
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissueTheodore P Ciaraldi, Deborah K Oh, Louis Christiansen, et al.
The Annals of Pharmacotherapy|November 8, 2015
Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex PatientsCandis M Morello, Melissa L D Christopher, Linda Ortega, et al.
Diabetes|January 29, 2002
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjectsYoung-Bum Kim, Theodore P Ciaraldi, Alice Kong, et al.
Pageof 16